EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Chugai Pharmaceutical Co's enterprise value is $50,470 Mil.
Chugai Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $3,131 Mil. Therefore, Chugai Pharmaceutical Co's EV-to-EBITDA for today is 16.12.
The historical rank and industry rank for Chugai Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
CHGCY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.03 Med: 21.94 Max: 39.8
Current: 16.12
During the past 13 years, the highest EV-to-EBITDA of Chugai Pharmaceutical Co was 39.80. The lowest was 9.03. And the median was 21.94.
CHGCY's EV-to-EBITDA is ranked worse than 61.24% of 707
companies
in the Drug Manufacturers industry
Industry Median: 13.81
vs CHGCY: 16.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Chugai Pharmaceutical Co's stock price is $16.79.
Chugai Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.697. Therefore, Chugai Pharmaceutical Co's PE Ratio for today is 24.09.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Chugai Pharmaceutical Co EV-to-EBITDA Historical Data
The historical data trend for Chugai Pharmaceutical Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's EV-to-EBITDA falls into.
Chugai Pharmaceutical Co EV-to-EBITDA Calculation
Chugai Pharmaceutical Co's EV-to-EBITDA for today is calculated as:
Chugai Pharmaceutical Co's current Enterprise Value is $50,470 Mil.
Chugai Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,131 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (OTCPK:CHGCY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Chugai Pharmaceutical Co's PE Ratio for today is calculated as:
Chugai Pharmaceutical Co's share price for today is $16.79.
Chugai Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.697.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Chugai Pharmaceutical Co EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.
Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHGCY has been successfully added to your 